HK1190912A1 - Treatment of metastatic stage prostate cancer with degarelix - Google Patents

Treatment of metastatic stage prostate cancer with degarelix

Info

Publication number
HK1190912A1
HK1190912A1 HK14103602.8A HK14103602A HK1190912A1 HK 1190912 A1 HK1190912 A1 HK 1190912A1 HK 14103602 A HK14103602 A HK 14103602A HK 1190912 A1 HK1190912 A1 HK 1190912A1
Authority
HK
Hong Kong
Prior art keywords
degarelix
treatment
prostate cancer
stage prostate
metastatic stage
Prior art date
Application number
HK14103602.8A
Other languages
English (en)
Chinese (zh)
Inventor
Bo-Eric Persson
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39718285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1190912(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of HK1190912A1 publication Critical patent/HK1190912A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK14103602.8A 2008-02-11 2010-12-09 Treatment of metastatic stage prostate cancer with degarelix HK1190912A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2774108P 2008-02-11 2008-02-11
EP08250703 2008-02-29
US14795609P 2009-01-28 2009-01-28

Publications (1)

Publication Number Publication Date
HK1190912A1 true HK1190912A1 (en) 2014-07-18

Family

ID=39718285

Family Applications (4)

Application Number Title Priority Date Filing Date
HK14111736.0A HK1198243A1 (en) 2008-02-11 2010-12-09 METHOD OF TREATING PROSTATE CANCER WITH GNRH ANTAGONIST GnRH
HK14103602.8A HK1190912A1 (en) 2008-02-11 2010-12-09 Treatment of metastatic stage prostate cancer with degarelix
HK13103556.5A HK1176552A1 (en) 2008-02-11 2010-12-09 Method of treating prostate cancer with the gnrh antagonist degarelix gnrh
HK10111506.2A HK1145011A1 (en) 2008-02-11 2010-12-09 Treatment of metastatic stage prostate cancer with degarelix

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK14111736.0A HK1198243A1 (en) 2008-02-11 2010-12-09 METHOD OF TREATING PROSTATE CANCER WITH GNRH ANTAGONIST GnRH

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK13103556.5A HK1176552A1 (en) 2008-02-11 2010-12-09 Method of treating prostate cancer with the gnrh antagonist degarelix gnrh
HK10111506.2A HK1145011A1 (en) 2008-02-11 2010-12-09 Treatment of metastatic stage prostate cancer with degarelix

Country Status (25)

Country Link
US (15) US8841081B2 (ja)
EP (7) EP3360565A1 (ja)
JP (10) JP5924866B2 (ja)
KR (7) KR20180118830A (ja)
CN (4) CN107412726A (ja)
AU (2) AU2009213751B2 (ja)
BR (2) BRPI0908127A2 (ja)
CA (3) CA3235099A1 (ja)
CY (3) CY1115561T1 (ja)
DK (3) DK2249859T3 (ja)
EA (4) EA026521B1 (ja)
ES (3) ES2532709T3 (ja)
HK (4) HK1198243A1 (ja)
HR (3) HRP20140665T1 (ja)
IL (3) IL207295A (ja)
JO (1) JOP20090061B1 (ja)
MX (2) MX2010008816A (ja)
NZ (4) NZ587088A (ja)
PL (3) PL2505204T3 (ja)
PT (3) PT2249859E (ja)
RU (2) RU2504393C2 (ja)
SI (3) SI2505204T1 (ja)
TW (2) TWI539959B (ja)
WO (2) WO2009101530A1 (ja)
ZA (1) ZA201005697B (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JO3525B1 (ar) * 2008-02-11 2020-07-05 Ferring Int Center Sa علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
TWI508734B (zh) * 2009-05-01 2015-11-21 Ferring Int Ct Sa 用於前列腺癌之治療的組成物
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
FR2964323B1 (fr) * 2010-09-08 2012-11-09 Jean Pierre Raynaud Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
US9260480B2 (en) 2010-10-27 2016-02-16 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
MX2013010330A (es) 2011-03-09 2014-11-26 Richard G Pestell Líneas de célula cancerosa de próstata, signaturas de gen, y usos de las mismas.
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
JP6518585B2 (ja) 2012-05-14 2019-05-22 リチャード ジー． ペステル がんの治療のためのｃｃｒ５の修飾薬の使用
CN107569456A (zh) 2012-06-01 2018-01-12 辉凌公司 制造地加瑞克
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
EP3384930A1 (en) 2013-03-15 2018-10-10 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding
WO2014186608A1 (en) * 2013-05-15 2014-11-20 Adverse Events, Inc. System and method for surveillance and evaluation of safety risks associated with medical interventions
JP2017529388A (ja) 2014-08-26 2017-10-05 ベタニエン ホスピタル 炎症性病態の治療のための方法、薬剤および組成物
AU2016261770B2 (en) * 2015-05-12 2022-06-02 Drexel University Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same
WO2018138703A1 (en) * 2017-01-30 2018-08-02 Antev Limited A composition comprising at least one GNRH antagonist
KR20200070334A (ko) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
EP3781167A4 (en) 2018-04-19 2022-02-23 Abbvie Inc. METHOD OF TREATMENT OF HEAVY MENSTRUAL BLEEDING
AU2019315522A1 (en) * 2018-08-01 2021-02-18 Abbvie Inc. Dosing regimens for elagolix
RU2731002C1 (ru) * 2019-10-22 2020-08-26 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения рака предстательной железы
CN116407494B (zh) * 2023-03-02 2024-07-09 山东大学齐鲁医院 一种醋酸地加瑞克注射液及其制备方法、用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4072668A (en) 1973-11-06 1978-02-07 The Salk Institute For Biological Studies LH-RH Analogs
EP0002749B2 (en) 1977-12-26 1987-08-12 IHARA CHEMICAL INDUSTRY Co., Ltd. Process for producing aromatic monocarboxylic acid
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
DE593491T1 (de) 1991-04-25 1994-11-17 Romano S.-Cergue Deghenghi LHRH-Antagonisten.
ES2159516T5 (es) 1992-02-12 2005-05-01 Daikyo Gomu Seiko Ltd. Un instrumento medico.
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
JP3688381B2 (ja) 1995-03-10 2005-08-24 株式会社東芝 光ディスク原盤露光装置
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
US5710246A (en) 1996-03-19 1998-01-20 Abbott Laboratories Process for intermediates for the synthesis of LHRH antagonists
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5821230A (en) 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
WO1999026964A1 (en) 1997-11-20 1999-06-03 Ortho-Mcneil Pharmaceutical, Inc. LIQUID PHASE PROCESS FOR THE PREPARATION OF GnRH PEPTIDES
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
WO2000004897A1 (en) 1998-07-20 2000-02-03 Peptech Limited Bioimplant formulation
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20020103131A1 (en) 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
IL158969A0 (en) * 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070015713A1 (en) 2005-07-14 2007-01-18 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
US20060234918A1 (en) * 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
SE0104463D0 (sv) 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
ME00509B (me) 2002-09-27 2011-10-10 Zentaris Gmbh Oblik za terapijsku primjenu aktivnih peptida sa dugotrajnim oslobođenjem aktivnog sastojka i postupak za njihovo dobijanje
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
AR042815A1 (es) 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006069779A1 (en) 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
JP6078217B2 (ja) 2008-01-15 2017-02-08 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 粉末化されたタンパク質組成物及びその作製方法
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
WO2009102720A1 (en) * 2008-02-11 2009-08-20 Safety Syringes, Inc. Reconstitution means for safety device
ES2538828T3 (es) 2009-04-24 2015-06-24 Polypeptide Laboratories A/S Método para la fabricación de degarelix
TWI508734B (zh) 2009-05-01 2015-11-21 Ferring Int Ct Sa 用於前列腺癌之治療的組成物
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
US9260480B2 (en) 2010-10-27 2016-02-16 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN102204889B (zh) 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
KR20140063602A (ko) 2011-07-15 2014-05-27 훼링 비.브이. 피코설페이트 조성물을 투여하여 대장내시경의 시술 시기를 조절하는 방법
CN107569456A (zh) 2012-06-01 2018-01-12 辉凌公司 制造地加瑞克

Also Published As

Publication number Publication date
TW200938217A (en) 2009-09-16
KR20100126362A (ko) 2010-12-01
JP2018039814A (ja) 2018-03-15
JP2024028869A (ja) 2024-03-05
RU2504393C2 (ru) 2014-01-20
CY1116289T1 (el) 2017-02-08
EP2505204A2 (en) 2012-10-03
EA201300742A1 (ru) 2014-02-28
KR20180118830A (ko) 2018-10-31
NZ587057A (en) 2012-12-21
US20170290879A1 (en) 2017-10-12
EA017582B1 (ru) 2013-01-30
EA036695B1 (ru) 2020-12-09
US20200237854A1 (en) 2020-07-30
US10695398B2 (en) 2020-06-30
AU2009213751A1 (en) 2009-08-20
TW200938218A (en) 2009-09-16
SI2249859T1 (sl) 2014-08-29
US20220218782A1 (en) 2022-07-14
US20220323538A1 (en) 2022-10-13
KR101542480B1 (ko) 2015-08-07
US20220226422A1 (en) 2022-07-21
US9579359B2 (en) 2017-02-28
US20090203622A1 (en) 2009-08-13
EP2505204A3 (en) 2013-01-09
US9877999B2 (en) 2018-01-30
JP2022184898A (ja) 2022-12-13
CY1116341T1 (el) 2017-02-08
CN101939020B (zh) 2012-12-26
CA2714444A1 (en) 2009-08-20
MX2010008817A (es) 2010-09-09
PT2650012E (pt) 2015-06-30
US8841081B2 (en) 2014-09-23
EP2249859A1 (en) 2010-11-17
IL207400A (en) 2014-12-31
JP6618967B2 (ja) 2019-12-11
KR20220009504A (ko) 2022-01-24
IL207295A0 (en) 2010-12-30
JP2011511785A (ja) 2011-04-14
DK2505204T3 (da) 2015-03-16
AU2009213748B9 (en) 2014-05-22
HK1176552A1 (en) 2013-08-02
KR20230088848A (ko) 2023-06-20
KR20100123714A (ko) 2010-11-24
US20220031801A1 (en) 2022-02-03
RU2010133481A (ru) 2012-03-20
JP2014167009A (ja) 2014-09-11
US11826397B2 (en) 2023-11-28
HRP20150290T1 (hr) 2015-04-10
PL2249859T3 (pl) 2014-10-31
NZ603932A (en) 2014-04-30
CA3235099A1 (en) 2009-08-20
EA201300741A1 (ru) 2014-02-28
AU2009213748B2 (en) 2014-03-13
SI2505204T1 (sl) 2015-04-30
RU2010133480A (ru) 2012-03-20
JP6189234B2 (ja) 2017-08-30
CA2714445A1 (en) 2009-08-20
HRP20140665T1 (hr) 2014-10-10
RU2504394C2 (ru) 2014-01-20
EP3360565A1 (en) 2018-08-15
PT2505204E (pt) 2015-03-26
ZA201005697B (en) 2014-01-24
JP2011511786A (ja) 2011-04-14
EA026521B1 (ru) 2017-04-28
US20210128673A1 (en) 2021-05-06
DK2650012T3 (da) 2015-06-15
JOP20090061B1 (ar) 2021-08-17
EA200901074A1 (ru) 2010-04-30
US20130029910A1 (en) 2013-01-31
TWI442932B (zh) 2014-07-01
KR20150091543A (ko) 2015-08-11
EP4257197A3 (en) 2023-11-29
JP2014141505A (ja) 2014-08-07
US9415085B2 (en) 2016-08-16
US20170035833A1 (en) 2017-02-09
US20140349935A1 (en) 2014-11-27
CN101939020A (zh) 2011-01-05
CN101998861A (zh) 2011-03-30
EP2650012A1 (en) 2013-10-16
NZ587088A (en) 2012-12-21
IL207400A0 (en) 2010-12-30
AU2009213751B2 (en) 2014-09-25
DK2249859T3 (da) 2014-06-02
JP5876652B2 (ja) 2016-03-02
US11766468B2 (en) 2023-09-26
EP2505204B1 (en) 2014-12-24
BRPI0908129A2 (pt) 2015-08-04
EP2650012B1 (en) 2015-03-25
US20090203623A1 (en) 2009-08-13
HRP20150633T1 (hr) 2015-07-31
EA020543B1 (ru) 2014-12-30
EP2799085A1 (en) 2014-11-05
ES2532709T3 (es) 2015-03-31
SI2650012T1 (sl) 2015-06-30
IL223124A0 (en) 2012-12-31
AU2009213748A1 (en) 2009-08-20
CA2714445C (en) 2018-01-16
EA200901075A1 (ru) 2010-04-30
JP2022133426A (ja) 2022-09-13
CN103990107A (zh) 2014-08-20
CY1115561T1 (el) 2017-01-04
ES2540235T3 (es) 2015-07-09
MX2010008816A (es) 2010-09-07
WO2009101533A1 (en) 2009-08-20
HK1198243A1 (en) 2015-03-20
IL207295A (en) 2015-03-31
PL2650012T3 (pl) 2015-08-31
US20140113870A1 (en) 2014-04-24
WO2009101530A1 (en) 2009-08-20
ES2479441T3 (es) 2014-07-24
EP2249858A1 (en) 2010-11-17
TWI539959B (zh) 2016-07-01
US20220218783A1 (en) 2022-07-14
HK1145011A1 (en) 2011-03-25
EP4257197A2 (en) 2023-10-11
PT2249859E (pt) 2014-07-31
JP2016216455A (ja) 2016-12-22
JP2016193910A (ja) 2016-11-17
US10729739B2 (en) 2020-08-04
NZ603958A (en) 2013-03-28
PL2505204T3 (pl) 2015-05-29
EP2249859B1 (en) 2014-04-23
JP6254042B2 (ja) 2017-12-27
KR20140130757A (ko) 2014-11-11
JP7400029B2 (ja) 2023-12-18
BRPI0908127A2 (pt) 2015-08-04
JP5924866B2 (ja) 2016-05-25
CN107412726A (zh) 2017-12-01
US10973870B2 (en) 2021-04-13
US20190167755A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
HK1145011A1 (en) Treatment of metastatic stage prostate cancer with degarelix
ZA201008140B (en) Treatment of metastatic tumors
EP2461814A4 (en) PROSTATE CANCER TREATMENT
IL215108A0 (en) Amatoxin-armed target-binding moieties for the treatment of cancer
HK1175476A1 (en) Cancer treatment
IL218575A0 (en) Treatment of cancer
IL217291A0 (en) Exosome based treatment of cancer
EP2310006A4 (en) TREATMENT OF CANCER
EP2197533A4 (en) ABLATION OF PROSTATE CANCER
ZA201107879B (en) Composition for the treatment of prostate cancer
GB0804496D0 (en) Treating cancer
PL388252A1 (pl) Terapia skojarzona raka jelita grubego
GB0916686D0 (en) Treatment of cancer
HK1258957A1 (zh) 用地加瑞克治療轉移階段前列腺癌
GB0809046D0 (en) Cancer treatment
GB0822016D0 (en) Treatment of metastatic cancer
GB0705205D0 (en) Treatment of metastatic cancer
AU2008906236A0 (en) Prostate Cancer Treatment Rectal Probe
GB0822018D0 (en) Prevention of metastatic cancer
GB0612369D0 (en) Treatment of metastatic cancer
GB0712513D0 (en) Treatment of cancer
GB0921757D0 (en) Treatment of cancer
GB0809730D0 (en) Improvements in the chemotherapy of cancer
GB0818566D0 (en) Improvements in the chemotherapy of cancer
GB0813361D0 (en) Treatment of cancer fatigue